Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease

NCT00428389 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00428389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00428389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
February 29, 2008
Enrollment
262 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease